M&A Healthcare Advisors Facilitates Sale of Innovo Detox to R&S Holdings
M&A Healthcare Advisors (MAHA) has advised the sale of Pennsylvania-based substance use disorder treatment provider, Innovo Detox, to Maryland-based behavioral health organization R&S Holdings. The acquisition adds an established clinical operation to R&S's growing platform and aligns with its strategy for expanding high-quality addiction services in the Mid-Atlantic region. The transaction was structured as a standalone deal, requiring careful coordination between legal teams on both sides due to regulatory complexities inherent in behavioral health M&A. MAHA led the process under Managing Director Andre Ulloa and Senior Associate Mike Abud, ensuring an efficient timeline despite challenges related to licensing and insurance reimbursement. Innovo Detox is known for its strong clinical reputation and patient care outcomes, making it a strategic acquisition target. R&S Holdings expressed satisfaction with MAHA's execution of the deal, citing their understanding of both transactional mechanics and operational realities in addiction treatment.
Topics: Acquisition Healthcare Substance Use Disorder Treatment